Complement Inhibitor

Complement Inhibitors

Hemoglobinuria, Paroxysmal

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-8"></a><h1>11 DESCRIPTION</h1>EMPAVELI contains pegcetacoplan, a complement inhibitor. Pegcetacoplan is a symmetrical molecule comprised of two identical pentadecapeptides covalently bound to the ends of a linear 40-kiloDalton (kDa) PEG molecule. The peptide portions of pegcetacoplan contain 1-methyl-L-tryptophan (Trp(Me)) in position 4 and amino(ethoxyethoxy)acetic acid (AEEA) in position 14.The molecular weight of pegcetacoplan is approximately 43.5 kDa. The molecular formula is C1970H3848N50O947S4. The structure of pegcetacoplan is shown below.<img alt="Chemical Structure" src="pegcetacoplan-01.jpg"/>EMPAVELI injection is a sterile, clear, colorless to slightly yellowish aqueous solution for subcutaneous use and is supplied in a 20-mL single-dose vial. Each 1 mL of solution contains 54 mg of pegcetacoplan, 41 mg of sorbitol, 0.384 mg of glacial acetic acid, 0.490 mg of sodium acetate trihydrate, and Water for Injection USP. EMPAVELI may also contain sodium hydroxide and/or additional glacial acetic acid for adjustment to a target pH of 5.0.</section>

Empaveli

pegcetacoplan

20 ML pegcetacoplan 54 MG/ML Injection

20 ML pegcetacoplan 54 MG/ML Injection [Empaveli]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event

Prescribing Information

Medication Guide

Pharmacy List

Coverage Authorization Request

Coverage Authorization Appeals

Letter of Medical Necessity

ApellisAssist Start Form

ApellisAssist Start Form - Spanish

Enroll in Patient Savings Program

Bridge Program

Apellis Care Coordinator & Care Educator

Free Trial Offer Form

Other HCP Resources

About Empaveli

Side Effects

Taking Empaveli

FAQs: Paroxysmal Nocturnal Hemoglobinuria (PNH)

Patient Stories

Patient Resources

Empaveli Start Guide

Patient Travel Guide

Empaveli Travel Letter

Patient Brochure

Instructions For Use (Injector): Paroxysmal Nocturnal Hemoglobinuria (PNH)

Instructions For Use (Infusion Pump): Paroxysmal Nocturnal Hemoglobinuria (PNH)

Instructions For Use (Infusion Pump): Paroxysmal Nocturnal Hemoglobinuria (PNH) - Spanish